| 8244- | LCA, | Licochalcone A from licorice root, an inhibitor of human hepatoma cell growth via induction of cell apoptosis and cell cycle arrest |
| - | in-vitro, | Liver, | HepG2 |
| 8243- | LCA, | Licochalcone A Inhibits Cellular Motility by Suppressing E-cadherin and MAPK Signaling in Breast Cancer |
| - | in-vitro, | BC, | MDA-MB-231 |
| 8242- | LCA, | Nrf2 signaling and autophagy are complementary in protecting lipopolysaccharide/d-galactosamine-induced acute liver injury by licochalcone A |
| - | in-vivo, | LiverDam, | NA |
| 8241- | LCA, | Licochalcone A induces apoptotic cell death via JNK/p38 activation in human nasopharyngeal carcinoma cells |
| - | in-vitro, | NPC, | NA |
| 8239- | LCA, | Licochalcone A, a licorice flavonoid: antioxidant, cytotoxic, genotoxic, and chemopreventive potential |
| - | Study, | Nor, | NA |
| 8238- | LCA, | Licochalcone A is a Natural Selective Inhibitor of Arginine Methyltransferase 6 |
| - | in-vitro, | BC, | MCF7 | - | in-vivo, | NA, | MCF10 |
| 8254- | LCA, | Geld, | Licochalcone A enhances geldanamycin-induced apoptosis through reactive oxygen species-mediated caspase activation |
| - | in-vitro, | Ovarian, | NA |
| 8250- | LCA, | Induction of NAD(P)H:Quinone Oxidoreductase 1 (NQO1) by Glycyrrhiza Species Used for Women's Health: Differential Effects of the Michael Acceptors Isoliquiritigenin and Licochalcone A |
| - | in-vivo, | Hepat, | NA |
| 8251- | LCA, | Licochalcone A inhibits the migration and invasion of human lung cancer cells via inactivation of the Akt signaling pathway with downregulation of MMP-1/-3 expression |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H460 |
| 8252- | LCA, | Effects of licochalcone A on the bioavailability and pharmacokinetics of nifedipine in rats: possible role of intestinal CYP3A4 and P-gp inhibition by licochalcone A. |
| - | in-vivo, | Nor, | NA |
| 8253- | LCA, | Licochalcone A, a natural chalconoid isolated from Glycyrrhiza inflata root, induces apoptosis via Sp1 and Sp1 regulatory proteins in oral squamous cell carcinoma |
| - | in-vitro, | SCC, | HSC4 |
| 8255- | LCA, | Antitumor and antimetastatic effects of licochalcone A in mouse models |
| - | in-vivo, | Colon, | NA |
| 8256- | LCA, | Licochalcone A inhibits the growth of colon carcinoma and attenuates cisplatin-induced toxicity without a loss of chemotherapeutic efficacy in mice |
| - | in-vivo, | Colon, | CT26 |
| 8257- | LCA, | Licochalcone A inhibiting proliferation of bladder cancer T24 cells by inducing reactive oxygen species production |
| - | in-vitro, | CRC, | T24/HTB-9 |
| 8258- | LCA, | Licochalcone A potently inhibits tumor necrosis factor alpha-induced nuclear factor-kappaB activation through the direct inhibition of IkappaB kinase complex activation |
| - | in-vitro, | Nor, | NA |
| 8259- | LCA, | Modulation of bcl-2 and cytotoxicity by licochalcone-A, a novel estrogenic flavonoid |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | AML, | HL-60 |
| 8260- | LCA, | Licochalcone A Induces Ferroptosis in Hepatocellular Carcinoma via Reactive Oxygen Species Activated by the SLC7A11/GPX4 Pathway |
| - | vitro+vivo, | Liver, | HepG2 | - | in-vitro, | Liver, | HUH7 |
| 8261- | LCA, | Licochalcone A induces T24 bladder cancer cell apoptosis by increasing intracellular calcium levels |
| - | in-vitro, | CRC, | T24/HTB-9 |
| 8275- | LCA, | Licochalcone A inhibits glioma migration, invasion, and growth by triggering mitochondrial dysfunction and ROS-mediated oxidative damage |
| - | vitro+vivo, | GBM, | NA |
| 8219- | LCA, | Licochalcone A Ameliorates Cognitive Dysfunction in an Alzheimer's Disease Model by Inhibiting Endoplasmic Reticulum Stress-Mediated Apoptosis |
| - | in-vivo, | AD, | NA |
| 8213- | LCA, | Licochalcone A inhibits hypoxia-inducible factor-1α accumulation by suppressing mitochondrial respiration in hypoxic cancer cells |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Lung, | H1299 | - | in-vitro, | Lung, | H322 |
| 8212- | LCA, | Licochalcone A inhibits proliferation and promotes apoptosis of colon cancer cell by targeting programmed cell death-ligand 1 via the NF-κB and Ras/Raf/MEK pathways |
| - | in-vitro, | Colon, | HepG3 | - | in-vitro, | Lung, | A549 | - | in-vitro, | Cerv, | HeLa | - | vitro+vivo, | CRC, | HCT116 |
| 8211- | LCA, | Licochalcone A induces endoplasmic reticulum stress-mediated apoptosis of endometrial cancer cells via upregulation of GRP78 expression |
| - | in-vitro, | EC, | NA |
| 8210- | LCA, | Licochalcone A-Induced Human Bladder Cancer T24 Cells Apoptosis Triggered by Mitochondria Dysfunction and Endoplasmic Reticulum Stress |
| - | in-vitro, | Bladder, | T24/HTB-9 |
| 8209- | LCA, | Licochalcone A Exerts Anti-Cancer Activity by Inhibiting STAT3 in SKOV3 Human Ovarian Cancer Cells |
| - | in-vitro, | Ovarian, | SKOV3 |
| 8208- | LCA, | Licochalcone A inhibits PI3K/Akt/mTOR signaling pathway activation and promotes autophagy in breast cancer cells |
| - | in-vitro, | BC, | MCF7 |
| 8207- | LCA, | Licochalcone a Induces ROS-Mediated Apoptosis through TrxR1 Inactivation in Colorectal Cancer Cells |
| - | in-vitro, | CRC, | HCT116 |
| 8206- | LCA, | Licochalcone A-induced human gastric cancer BGC-823 cells apoptosis by regulating ROS-mediated MAPKs and PI3K/AKT signaling pathways |
| - | in-vivo, | GC, | BGC-823 |
| 8214- | LCA, | Licochalcone A decreases cancer cell proliferation and enhances ferroptosis in acute myeloid leukemia through suppressing the IGF2BP3/MDM2 cascade |
| - | vitro+vivo, | AML, | U937 |
| 8215- | LCA, | Determination of licochalcone A in rat plasma by UPLC–MS/MS and its pharmacokinetics |
| - | in-vivo, | Nor, | NA |
| 8216- | LCA, | Effects of licochalcone A on the bioavailability and pharmacokinetics of nifedipine in rats: possible role of intestinal CYP3A4 and P-gp inhibition by licochalcone A |
| - | in-vivo, | Nor, | NA |
| 8217- | LCA, | Inhibition of human cytochrome P450 enzymes by licochalcone A, a naturally occurring constituent of licorice |
| - | Study, | Nor, | NA |
| 8218- | LCA, | Advances in Pharmacological Activities and Drug Delivery Systems of Licochalcone A |
| - | Review, | Nor, | NA |
| 8220- | LCA, | Licochalcone a enhances cognitive resilience in APP/PS1 Mice by modulating glucose metabolism, Aβ burden, and neuroinflammation |
| - | in-vivo, | AD, | NA |
| 8221- | LCA, | Anti-inflammatory efficacy of Licochalcone A: correlation of clinical potency and in vitro effects |
| - | in-vitro, | Nor, | NA |
| 8231- | LCA, | Maintenance of the Expression of c-FLIPL by Hsp70 to Resist Licochalcone A-Induced Anti-Colorectal Cancer Effect through ERK-Mediated Autophagy Induction |
| - | in-vitro, | CRC, | NA |
| 8235- | LCA, | Anticancer effects of licochalcones: A review of the mechanisms |
| - | Review, | Var, | NA |
| 8234- | LCA, | Licochalcone A: A Potential Multitarget Drug for Alzheimer’s Disease Treatment |
| - | Review, | AD, | NA |
| 8233- | LCA, | Licochalcone A induces cell cycle arrest and apoptosis via suppressing MAPK signaling pathway and the expression of FBXO5 in lung squamous cell cancer |
| - | in-vitro, | Lung, | NA |
| 8232- | LCA, | Licochalcone A induces G2/M phase arrest and apoptosis via regulating p53 pathways in esophageal cancer: In-vitro and in-vivo study |
| - | vitro+vivo, | ESCC, | NA |
| 8222- | LCA, | Licochalcone A Induces Cholangiocarcinoma Cell Death Via Suppression of Nrf2 and NF-κB Signaling Pathways |
| - | in-vitro, | CCA, | KKU-100 | - | in-vitro, | CCA, | KKU-213 | - | in-vitro, | CCA, | KKU-214 | - | in-vitro, | CCA, | KKU-156 | - | in-vitro, | 0-Reserved, | KKU-452 |
| 8230- | LCA, | The Ameliorative Role of Lico A on Aflatoxin B1-Triggered Hepatotoxicity Partially by Activating Nrf2 Signal Pathway |
| - | vitro+vivo, | Nor, | NA |
| 8229- | LCA, | Licochalcone A: a review of its pharmacology activities and molecular mechanisms |
| - | Review, | Nor, | NA |
| 8228- | LCA, | Detection and pharmacokinetics of licochalcone A in brains of neuroinflammatory mouse model |
| - | in-vivo, | AD, | NA |
| 8227- | LCA, | Licochalcone A as Novel Multitarget Inhibitors via AChE, BuChE, and Synapsin III for Therapeutic Intervention Against Alzheimer’s Disease: Computer-Aided Drug Design |
| - | Study, | AD, | NA |
| 8226- | LCA, | Licochalcone A as a Potential Anti- Toxoplasma Agent: A Target Identification and Pharmacokinetic Study |
| - | Study, | Nor, | NA |
| 8225- | LCA, | Cisplatin, | Licochalcone A protects against cisplatin-induced acute kidney injury via the modulation of Nrf2/Keap1-mediated ferroptosis and apoptosis |
| - | in-vivo, | Nor, | NA |
| 8224- | LCA, | 3,3',4,4'-Tetrahydroxy-2-methoxychalcone from Glycyrrhiza uralensis roots inhibits HIF-1α and Nrf2, suppressing hypoxia-induced angiogenesis |
| - | in-vitro, | CRC, | HCT116 |
| 8223- | LCA, | Lico A Enhances Nrf2-Mediated Defense Mechanisms against t-BHP-Induced Oxidative Stress and Cell Death via Akt and ERK Activation in RAW 264.7 Cells |
| - | in-vitro, | Nor, | RAW264.7 |
| 8341- | LDN, | Low-Dose Naltrexone as an Adjuvant in Combined Anticancer Therapy |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid